Hydration Pharmaceuticals Co. Ltd. (AU:HPC)
ASX:HPC
Want to see AU:HPC full AI Analyst Report?
Top Page
Hydration Pharmaceuticals Co. Ltd.
(Sydney:HPC)
Select Model
Select Model
Rating:44Neutral
Price Target:
AU$0.01
▲(0.00% Upside)
Action:ReiteratedDate:03/02/26
The score is primarily constrained by weak financial performance—volatile and declining revenue, structurally unprofitable operations, and persistent negative operating/free cash flow—implying ongoing funding risk despite low reported debt. Valuation is also hindered by a negative P/E and no dividend yield data. Technical and earnings-call/event inputs were not available to improve or reduce the assessment.
Positive Factors
Low Financial Leverage
Reported zero debt in 2024–2025 materially lowers solvency risk and gives management longer optionality to raise capital or restructure financing without servicing existing debt. Over 2–6 months this supports strategic flexibility for funding product development, marketing, or working capital needs.
Negative Factors
Persistent Cash Burn
Consistent negative operating and free cash flow, with 2025 OCF worsening to ~-3.8M, implies the business cannot self-fund. Over a 2–6 month horizon this elevates funding risk, increases likelihood of external financing or dilution, and constrains investment in distribution, product development, or working capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Financial Leverage
Reported zero debt in 2024–2025 materially lowers solvency risk and gives management longer optionality to raise capital or restructure financing without servicing existing debt. Over 2–6 months this supports strategic flexibility for funding product development, marketing, or working capital needs.
Read all positive factors
Hydration Pharmaceuticals Co. Ltd. (HPC) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$1.72M
Dividend YieldN/A
Average Volume (3M)1.21M
Price to Earnings (P/E)―
Beta (1Y)0.31
Revenue GrowthN/A
EPS GrowthN/A
CountryAU
EmployeesN/A
SectorConsumer Defensive
Sector Strength42
IndustryFood Distribution
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding430,800,930
10 Day Avg. Volume3,315,133
30 Day Avg. Volume1,207,806
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.91
Price to Sales (P/S)0.51
P/FCF Ratio-0.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Hydration Pharmaceuticals Co. Ltd. Business Overview & Revenue Model
Company Description
Hydration Pharmaceuticals Co. Ltd. (HPC) is a company specializing in the development, manufacturing, and distribution of innovative hydration solutions. Operating within the health and wellness sector, HPC focuses on providing high-quality, scien...
How the Company Makes Money
HPC generates revenue primarily through the sale of its hydration products, which are distributed across various channels including retail stores, e-commerce platforms, and direct-to-consumer sales. Key revenue streams include wholesale partnershi...
Hydration Pharmaceuticals Co. Ltd. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
42
Neutral
Cash Flow
12
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.56M | 3.20M | 10.04M | 9.10M | 6.13M |
| Gross Profit | -27.42K | 1.62M | 5.39M | 4.70M | 2.79M |
| EBITDA | -3.26M | -3.91M | -7.46M | -10.52M | -6.08M |
| Net Income | -2.96M | 2.67M | -8.10M | -10.61M | -8.97M |
Balance Sheet | |||||
| Total Assets | 2.19M | 5.00M | 6.69M | 10.39M | 15.31M |
| Cash, Cash Equivalents and Short-Term Investments | 1.12M | 3.22M | 1.84M | 4.69M | 10.67M |
| Total Debt | 0.00 | 0.00 | 3.89M | 3.71M | 0.00 |
| Total Liabilities | 774.76K | 2.25M | 7.05M | 6.41M | 2.08M |
| Stockholders Equity | 1.42M | 2.74M | -358.25K | 3.98M | 13.23M |
Cash Flow | |||||
| Free Cash Flow | -3.78M | -3.02M | -5.73M | -9.75M | -8.08M |
| Operating Cash Flow | -3.78M | -3.02M | -5.73M | -9.75M | -8.08M |
| Investing Cash Flow | 0.00 | 9.44M | 0.00 | 0.00 | -2.15K |
| Financing Cash Flow | 833.93K | -3.63M | 2.72M | 4.08M | 17.03M |
Hydration Pharmaceuticals Co. Ltd. Peers Comparison
UnderperformOutperform
Sector (62)
AU:HPC
Hydration Pharmaceuticals Co. Ltd.
0.01
0.00
0.00%
AU:CC5
LBT Innovations Limited
0.02
<0.01
16.67%
AU:LDX
Lumos Diagnostics Holdings Ltd.
0.17
0.14
466.67%
AU:HXL
Hexima Ltd
0.01
0.00
0.00%
Hydration Pharmaceuticals Co. Ltd. Corporate Events
Hydralyte North America Resets Around U.S. Core as Revenue Falls but Cost Base Shrinks
Feb 27, 2026
Hydralyte North America reported a 22.9% drop in FY2025 revenue to US$2.47 million as it deliberately narrowed channels and rationalised SKUs while exiting non‑U.S. operations to focus on a streamlined U.S.‑only business. The company p...
Hydralyte USA Maintains Steady Sales as Inventory Restock and Cost Cuts Aim to Drive 2026 Growth
Jan 30, 2026
Hydralyte USA reported Q4 FY25 net sales of US$540,000, broadly in line with prior quarters but constrained by an out-of-stock situation in its Hydralyte Variety Pack following a strong sales uplift through emerging U.S. distributors such as Cardi...
Hydration Pharmaceuticals Director Karafili Sees 500,000 Options Expire
Jan 7, 2026
The Hydration Pharmaceuticals Company Limited has reported a change in director Adem Karafili’s relevant interests following the expiry and cancellation of 500,000 unlisted options held indirectly through Ankara Holdings Pty Ltd as trustee s...
Hydration Pharmaceuticals Options Lapse, Simplifying Capital Structure
Jan 7, 2026
Hydration Pharmaceuticals has announced the lapse of 46,612,138 listed options (HPCAU), which expired unexercised on 31 December 2025 and were scheduled to convert at an exercise price of A$0.07. The expiry of this large block of options results i...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.